Even When Chemotherapy Stops Working, a Newly Approved Medicine Is Doubling Survival for Pancreatic Cancer Patients
The FDA has granted immediate approval to daraxonrasib, an insurance-covered therapy shown to double survival times for people facing advanced pancreatic cancer after standard chemotherapy has failed. While not a permanent cure, the drug provides meaningful additional months of living time against an illness historically considered among the most untreatable. The decision delivers an immediate, accessible lifeline to patients and families who previously had exhausted their clinical options.
Source: Good News Network
Read the original story →